Novel Molecular Targets for Mood Disorders and Psychosis: A Workshop

Workshop

March 8 - 9, 2021

Past

Discussion

This discussion information is being collected via Slido. Slido is not affiliated in any way with, or endorsed by, the National Academies of Sciences, Engineering, and Medicine, and your submission via the Slido website is subject to Slido’s privacy and terms of use.

Materials

About

A proceedings of the presentations and discussions at this March 8-9, 2021 workshop was be prepared by a designated rapporteur in accordance with NASEM’s institutional guidelines, and is available for download from the National Academies Press here. Additionally, the live-streamed video recording is available below.

Background

For many individuals living with mental illness, current pharmacological interventions are ineffective at delivering adequate relief from disabling symptoms. Despite the release of several generations of antidepressants, depression remains a leading cause of disability in the United States. Meanwhile, psychosis spectrum disorders are less well understood and generally more difficult to treat with drugs.

However, recent advances in understanding mechanisms of action (MOAs) have led to the identification of potential novel molecular targets in the neuropharmacology mood disorder – including glutamate receptors, GABA receptors, muscarinic acetylcholine receptors, the mTOR pathway, the TAAR1 pathway, and others. These promising avenues for further investigation have re-energized scientific research into new opportunities for targeted drug development for depression and psychosis- but there remain many open questions.

This virtual public workshop brought together experts and key stakeholders from academia, government, industry, and non-profit organizations to explore novel molecular targets in the neuropharmacology of mood disorders and psychosis.

Planning Committee Members

Linda Brady, National Institutes of Mental Health, Workshop Chair
Tiffany Farchione, Food and Drug Administration
David Gray, Cerevel Therapeutics
Magali Haas, Cohen Veterans Bioscience
Stuart Hoffman, U.S. Department of Veterans' Affairs
John Krystal, Yale University School of Medicine
Carlos Larrauri, National Alliance on Mental Illness
Husseini Manji, Johnson and Johnson Pharmaceutical Research and Development, LLC
Sharon Mates, Intracellular Therapies
Steve Paul, Karuna Therapeutics Inc.
Morgan Sheng, The Broad Institute of MIT and Harvard
Greg Simon, Kaiser Permanente Washington Health Research Institute
Ilina Singh, University of Oxford

Contact

Chanel Matney

(202) 334-2183
cmatney@nas.edu

Disclaimer

It is essential to the National Academies mission of providing evidence-based advice that participants in any of our meetings or events avoid political or partisan statements or commentary and maintain a culture of mutual respect. The statements and presentations during our meetings or events are solely those of the individual participants and do not necessarily represent the views of other participants or the National Academy of Sciences, which is a non-partisan, tax exempt organization that includes under its Charter the National Academy of Engineering and National Academy of Medicine, and that operates the National Research Council.

Log In

Sign in to access your saved publications, downloads, and email preferences.

Former MyNAP users: You'll need to reset your password on your first login to MyAcademies. Click "Forgot password" below to receive a reset link via email. Having trouble? Visit our FAQ page to contact support.

Members of the National Academy of Sciences, National Academy of Engineering, or National Academy of Medicine should log in through their respective Academy portals.

Email (required)
Password (required)

Don't have an account?

Register

Email (required)
New password (required)
Retype password (required) Password must be at least 8 characters
I accept the terms of use
terms of use

Thank You

Thank you for creating a MyAcademies account!

Enjoy free access to thousands of National Academies' publications, a 10% discount off every purchase, and build your personal library.

Forgot Password

Enter the email address for your MyAcademies (formerly MyNAP) account to receive password reset instructions.

Reset Requested

We sent password reset instructions to your email . Follow the link in that email to create a new password. Didn't receive it? Check your spam folder or contact us for assistance.

Reset Password

New password (required)
Retype password (required) Password must be at least 8 characters

Reset Password

Your password has been reset.

Log In

Verify email

Verify Your Email Address

We sent a verification link to your email. Please check your inbox (and spam folder) and follow the link to verify your email address. If you did not receive the email, you can request a new verification link below

Subscribe

First Name
Last Name
Email (required)
I agree to receive emails from the National Academies (required)

We respect your privacy and will never share your information.

My Academies

Novel Molecular Targets for Mood Disorders and Psychosis: A Workshop

Dropdown items

Novel Molecular Targets for Mood Disorders and Psychosis: A Workshop